Back to search

Article

Real-world experience of erenumab in patients with chronic or episodic migraine in the UAE

2022-02-16

Abstract excerpt

<h4>Background: </h4> Erenumab is a fully human monoclonal antibody and a highly potent, first-in-class calcitonin gene-related peptide receptor inhibitor approved for migraine prevention in adults. Randomised, placebo-controlled trials show that erenumab treatment results in clinically meaningful responses, including significant reductions in monthly migraine days. Real-world evidence of the effectiveness of eren...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
fee6ab61-b592-5f69-aa80-1e7d23250aa3
DOI
10.21203/rs.3.rs-1305232/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Real-world experience of erenumab in patients with chronic or episodic migraine in the UAEDOI 10.21203/rs.3.rs-1305232/v1
Real-world Evidence Data on the Monoclonal Antibody Erenumab in Migraine Prevention: Perspectives of Treating Physicians in GermanySemantic proximity
Different Doses of Erenumab for Preventive Treatment of Episodic Migraine: A Systematic Review and Network Meta-AnalysisSemantic proximity
Erenumab in highly therapy-refractory migraine patients First German Real-world evidenceSemantic proximity
Unveiling the Efficacy and Safety of Erenumab, a Monoclonal Antibody Targeting Calcitonin Gene-related Peptide (CGRP) Receptor, in Patients with Chronic and Episodic Migraine: A GRADE-assessed Systematic Review and Meta-analysis of Randomized Clinical Trials with Subgroup AnalysisSemantic proximity
Efficacy of fremanezumab in refractory chronic migraine patients: Real-world data from the Hull Migraine Clinic, UKSemantic proximity
Fremanezumab in the Prevention of High-Frequency Episodic and Chronic Migraine: A 12-Week, Multicenter, Real-Life, Cohort Study (The FRIEND Study).Semantic proximity
Efficacy and safety of calcitonin-gene-related peptide binding monoclonal antibodies for the preventive treatment of episodic migraine – An updated systematic review and meta-analysisSemantic proximity
Monoclonal Antibodies Against Calcitonin Gene-related Peptide for Migraine Prophylaxis: A Systematic Review of Real-world DataSemantic proximity
Efficacy and Safety of CGRP Monoclonal Antibodies for the Prevention of Migraine Compared with Placebo: A Systematic Review and Meta-AnalysisSemantic proximity
Two-year, real-world erenumab persistence and quality of life data in 82 pooled patients with abrupt onset, unremitting, treatment refractory headache and a migraine phenotype: New daily persistent headache or persistent post-traumatic headache in the majority of cases.Semantic proximity
Different Dosage Regimens of Eptinezumab for the Treatment of Migraine: A Meta-Analysis from Randomized Controlled TrialsSemantic proximity
An Investigation into the Prevalence of Migraine and its Prophylactic Treatment Patterns in the Czech RepublicSemantic proximity
Select a neighboring publication to make it the new centre.